Definitions

from Wiktionary, Creative Commons Attribution/Share-Alike License.

  • noun A human monoclonal antibody designed for the treatment of cancer of the head and neck.

Etymologies

Sorry, no etymologies found.

Examples

  • Genmab shares slumped 20.4% in Copenhagen after the Danish drug maker said that top-line results from a zalutumumab Phase III study in patients with recurrent or metastatic squamous cell carcinoma of the head and neck who failed standard platinum-based chemotherapy didn't meet its primary endpoint of demonstrating a statistically significant difference in overall survival.

    European Stocks Finish Flat

  • Genmab shares slumped 20.4% in Copenhagen after the Danish drug maker said that top-line results from a zalutumumab Phase III study in patients with recurrent or metastatic squamous cell carcinoma of the head and neck who failed standard platinum-based chemotherapy didn't meet its primary endpoint of demonstrating a statistically significant difference in overall survival.

    European Stocks Finish Flat

  • Genmab shares slumped 20.4% in Copenhagen after the Danish drug maker said that top-line results from a zalutumumab Phase III study in patients with recurrent or metastatic squamous cell carcinoma of the head and neck who failed standard platinum-based chemotherapy didn't meet its primary endpoint of demonstrating a statistically significant difference in overall survival.

    European Stocks Finish Flat

  • Genmab A/S has announced it has initiated a Phase II study of HuMax-EGFr (zalutumumab) in combinatio ...

    THE MEDICAL NEWS

  • Genmab A/S has announced it has initiated a Phase II study of HuMax-EGFr (zalutumumab) in combinatio ...

    THE MEDICAL NEWS

  • Genmab A/S has announced it has initiated a Phase II study of HuMax-EGFr (zalutumumab) in combinatio ...

    THE MEDICAL NEWS

  • In March, we announced top-line results from a zalutumumab Phase III study in refractory head and neck chemotherapy.

    THE MEDICAL NEWS

  • Patients in the study will be randomized into two treatment groups: zalutumumab in combination with best supportive care or best supportive care alone.

    News

  • COPENHAGEN, Denmark, Jan. 5, 2009 (GLOBE NEWSWIRE) -- Genmab A / S (OMX: GEN) announced today that the interim survival analysis of the Phase III pivotal study investigating zalutumumab

    News

  • The objective of the study is to evaluate the efficacy of zalutumumab incombination with best supportive care as compared to best supportive care alone in terms of overall survival.

    News

Comments

Log in or sign up to get involved in the conversation. It's quick and easy.